Combotope Therapeutics Enters into Collaboration with Boehringer Ingelheim to Advance First-in-Class Tumor-Selective Antibody Therapies for Cancer
· Collaboration spans multiple oncology targets and combines Combotope’s SMART-Phage™ discovery platform with Boehringer Ingelheim’s research and development expertise. · Dual recognition of a cancer-linked sugar pattern and its protein carrier enables highly tumor-selective antibody targeting. Copenhagen, Denmark – 23rd June — Combotope Therapeutics ApS (“Combotope”), a biotechnology company focused on discovering tumor-selective antibodies against cancer-specific glycan–protein targets, today announced a strategic research collaboration with Boehringer Ingelheim. The